We evaluated the efficacy and safety of vigabatrin in focal epilepsy associated with tuberous sclerosis complex by retrospectively reviewing patients with focal epilepsy and tuberous sclerosis complex treated with vigabatrin at a pediatric epilepsy center over an 8-year period. Of 85 patients, 20 (23.5%) were seizure-free for >12 months, 45 (52.9%) were responders (≥50% seizure reduction), and 20 (23.5%) were nonresponders. The median age (in months) at seizure onset in the seizure-free group (median, 15; interquartile range [IQR], 6-23.3) was higher than that of responders (median, 5; IQR, 3-14) and nonresponders (median, 6; IQR, 2-12). Fewer patients in the seizure-free group had calcification in their largest tubers, but the presence of tuber calcification did not differ among groups. Vigabatrin is more likely to result in seizure freedom in children with tuberous sclerosis complex who have later infantile onset of focal seizures and no calcification in their largest tuber.

中文翻译：

---

结节性硬化症患儿的局灶性癫痫：氨己烯酸能否控制局灶性癫痫发作？

我们通过回顾性回顾在儿童癫痫中心接受氨己烯酸治疗的局灶性癫痫和结节性硬化症患者 8 年，评估了氨己烯酸治疗与结节性硬化症相关的局灶性癫痫的疗效和安全性。在 85 名患者中，20 名（23.5%）无癫痫发作超过 12 个月，45 名（52.9%）有反应（癫痫发作减少≥50%），20 名（23.5%）无反应。无癫痫发作组癫痫发作的中位年龄（以月为单位）（中位数，15；四分位距 [IQR]，6-23.3）高于应答者（中位数，5；IQR，3-14）和无应答者（中位数，6；IQR，2-12）。无癫痫发作组中较少的患者在其最大的块茎中出现钙化，但块茎钙化的存在在各组之间没有差异。